Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2, 2004, Pages 445-453

  Milano, Michael T ^a   Chmura, Steven J ^a   Garofalo, Michael C ^a   Rash, Carla ^a   Roeske, John C ^a   Connell, Phillip P ^a   Kwon, Oh Hoon ^a   Jani, Ashesh B ^a   Heimann, Ruth ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Cholangiocarcinoma; Intensity modulated radiotherapy; Pancreatic cancer

Indexed keywords

BIOLOGICAL ORGANS; CARCINOGENS; RADIOTHERAPY; TOXICITY; TUMORS;

CARCINOMA; INTENSITY-MODULATED RADIOTHERAPY (IMRT);

ONCOLOGY;

ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE;

ADD ON THERAPY; ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSIMETRY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTHESIS; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; KIDNEY; LIVER; METASTASIS; NAUSEA; NEUROECTODERM TUMOR; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SMALL INTESTINE; STOMACH; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; FLUOROURACIL; HUMANS; IMAGING, THREE-DIMENSIONAL; MIDDLE AGED; NEUROECTODERMAL TUMORS; PANCREATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL;

EID: 2442593990     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.11.003     Document Type: Article

References (44)

1. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: Current status and issues of interest. Int J Radiat Oncol Biol Phys 2001;51:880-914
2. Crane C.H., Antolak J.A., Rosen I.I., et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer. 30:2001;123-132
3. Landry J.C., Esiashvili N., Ting J.Y., et al. Intensity modulated radiation therapy employing the volume at risk approach to minimize small bowel and renal toxicity when treating patients with locally advanced pancreatic carcinomas. [Abstract] Int J Radiat Oncol Biol Phys. 51:2001;270
4. Landry J.C., Yang G.Y., Ting J.Y., et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA) Employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim. 27:2002;121-129
5. Mell L.K., Roeske J.C., Mundt A.J. A survey of intensity-modulated radiation therapy use in the United States. Cancer. 98:2003;204-211
6. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21:1991;109-122
7. Lyman J.T. Complication probability as assessed from dose volume histograms. Radiat Res. 8S:1985;513-519
8. Lawrence T.S., Kessler M.L., Ten Haken R.K. Clinical interpretation of dose-volume histograms The basis for normal tissue preservation and tumor dose escalation. Front Radiat Ther Oncol. 29:1996;57-66
9. Lawrence T.S., Ten Haken R.K., Kessler M.L., et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 23:1992;781-788
10. Flentje M., Hensley F., Gademann G., et al. Renal tolerance to nonhomogenous irradiation Comparison of observed effects to predictions of normal tissue complication probability from different biophysical models. Int J Radiat Oncol Biol Phys. 27:1993;25-30
11. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1995;1237-1248
12. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 53:2002;810-821
13. Baglan K.L., Frazier R.C., Yan D., et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 52:2002;176-183
14. Glatstein E. Letter to the editor. Int J Radiat Oncol Biol Phys. 56:2003;1507-1508
15. Rasmussen HS, Lemipicki M, Chu KW, et al. TNFerade biologic, a gene transfer/radiation approach to deliver TNF-alpha: Summary of preclinical toxicity and pharmacokinetics [Abstract]. Proc Am Soc Clin Oncol 2001;19:451
16. Hanna N, Nemunaitis J, Cunningham CC, et al. A phase I study of tumor necrosis factor-alpha gene transfer with radiation for advanced solid tumors [Abstract]. Proc Am Soc Clin Oncol 2002;20:344
17. Vijayakumar S, Mundt AJ, Nemunaitis J, et al. TNFerade, an adenovector encoding the human tumor necrosis factor alpha gene, in soft tissue sarcoma: A phase I study [Abstract]. Proc Am Soc Clin Oncol 2003;21:3292
18. International Commission on Radiation Units and Measurements (ICRU). Report number 50: Prescribing, recording and reporting photon beam therapy. 1993;ICRU, Washington DC
19. Chen G.T., Jiang S.B., Kung J., et al. Abdominal organ motion and deformation Implications for IMRT. [Abstract] Int J Radiat Oncol Biol Phys. 51:2001;210
20. Sailer S.L., Chaney E.L., Rosenman J.G., et al. Three dimensional treatment planning at the University of North Carolina at Chapel Hill. Semin Radiat Oncol. 2:1992;267-273
21. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:2000;13-47
22. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer. 48:1981;1705-1710. for the Gastrointestinal Tumor Study Group
23. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 80:1988;751-755
24. Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer. 56:1985;2563-2568
25. Kalser M.H., Ellenberg S.S. Pancreatic cancer Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 120:1985;899-903
26. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 59:1987;2006-2010
27. Yeo C.J., Cameron J.L., Sohn T.A., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s Pathology, complications, and outcomes. Ann Surg. 226:1997;248-260
28. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas - 616 patients Results, outcomes, and prognostic indicators. J Gastrointest Surg. 4:2000;567-579
29. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 230:1999;776-784
30. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer A randomised controlled trial. Lancet. 358:2001;1576-1585
31. Neoptolemos J.P., Stocken D.D., Dunn J.A., et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 234:2001;758-768
32. Regine W.F., Abrams R.A. Adjuvant therapy for pancreatic cancer Back to the future. Int J Radiat Oncol Biol Phys. 42:1998;59-63
33. Abrams R.A., Lillemoe K.D., Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 358:2001;1565-1566
34. Nakeeb A., Tran K.Q., Black M.J., et al. Improved survival in resected biliary malignancies. Surgery. 132:2002;555-564
35. Kim S., Kim S.W., Bang Y.J., et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 54:2002;414-419
36. Whittington R., Neuberg D., Tester W.J., et al. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma A phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol. 13:1995;227-232
37. Minsky B.D., Kemeny N., Armstrong J.G., et al. Extrahepatic biliary system cancer An update of a combined modality approach. Am J Clin Oncol. 14:1991;433-437
38. Haslam J.B., Cavanaugh P.J., Stroup S.L. Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer. 32:1973;1341-1347
39. Wolff R.A., Evans D.B., Gravel D.M., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 7:2001;2246-2253
40. Crane C.H., Abbruzzese J.L., Evans D.B., et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 52:2002;1293-1302
41. Whittington R., Bryer M.P., Haller D.G., et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 21:1991;1137-1143
42. Willett C.G., Lewandrowski K., Warshaw A.L., et al. Resection margins in carcinoma of the head of the pancreas Implications for radiation therapy. Ann Surg. 217:1993;144-148
43. Mu X., Lofroth P.O., Karlsson M., et al. The effect of fraction time in intensity modulated radiotherapy Theoretical and experimental evaluation of an optimisation problem. Radiother Oncol. 68:2003;181-187
44. Bussels B., Goethals L., Feron M., et al. Respiration-induced movement of the upper abdominal organs A pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol. 68:2003;69-74